Prognostic significance of residual disease in patients with Stage IV epithelial ovarian cancer

Gynecologic Oncology

Volumn 64, Issue 1, 1997, Pages 13-17

  Munkarah, Adnan R ^a,b   Hallum III, Alton V ^a,c   Morris, Mitchell ^a   Burke, Thomas W ^a   Levenback, Charles ^a   Atkinson, E Neely ^a   Wharton, J Taylor ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; DEEP VEIN THROMBOSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HUMAN; HYSTERECTOMY; INTESTINE SURGERY; LIVER METASTASIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PLEURA METASTASIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY; SPLENECTOMY; SURVIVAL TIME;

EID: 0031032398     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4540     Document Type: Article

References (28)

1. 1. American Cancer Society. Cancer facts and figures - 1996, American Cancer Society (1996).
2. 2. Munnell, E. W. The changing prognosis and treatment in cancer of the ovary: A report of 235 patients with primary ovarian carcinoma 1952-1961, Am. J. Obstet. Gynecol. 100, 790-805 (1968).
3. 3. Griffiths, C. T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma, Natl. Cancer Inst. Monogr. 42, 101-104 (1975).
4. 4. Young, R. C., Chabner, B. A., Hubbard, S. P., Fisher, R. I., Bender, R. A., Anderson, T., Simon, R. M., Canellos, G. P., and De Vita, V. T., Jr. Advanced ovarian adenocarcinoma: A prospective clinical trail of melphalan (L-PAM) versus combination chemotherapy, N. Engl. J. Med. 299, 1261-1266 (1978).
5. 5. Smith, J., and Day, T. Review of ovarian cancer at the University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Am. J. Obstet. Gynecol. 135, 984-993 (1979).
6. 6. Blythe, J. G., and Wahl, T. P. Debulking surgery: Does it increase the quality of survival? Gynecol. Oncol. 14, 396-408 (1982).
7. 7. Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., and Elashoff, R. M. Primary cytoreductive surgery for epithelial ovarian cancer, Obstet. Gynecol. 61, 413-420 (1983).
8. 8. Delgado, G., Oram, D. H., and Petrilli, E. S. Stage III epithelial ovarian cancer: The role of maximal surgical reduction, Gynecol. Oncol. 18, 293-298 (1984).
9. 9. Wharton, J., and Edwards, C. Cytoreductive surgery for common epithelial tumors of the ovary, Clin. Obstet. Gynecol. 10, 235 (1984).
10. 10. Neijt, J. P., ten Bokkel Huinink, W. W., van der Berg, M. E. L., van Oosteroon, A. T., Vriesendorp, R., Kooyman, C. D., van Lindert, A. C. M., Hamerlynck, J. V. T. H., van Lent, M., van Houwelingen, J. C., and Pinedo, H. M. Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma, Lancet 2, 594-600 (1984).
11. 11. Redman, J. R., Petrini, G. R., Saigo, P.E., Geller, N. L., and Hakes, T. B. Prognostic factors in advanced ovarian carcinoma, J. Clin. Oncol. 4, 515-523 (1986).
12. 12. Heintz, A. P. M., Hacker, N. F., Berek, J. S., Rose, T. P., Munoz, A. K., and Lagasse, L. D. Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity, Obstet. Gynecol. 67, 783-788 (1986).
13. 13. Omura, G. A., Bundy, B. N., Berek, J. S., Curry, S., Delgado, G., and Mortel, R. Randomized trail of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study, J. Clin. Oncol. 7, 457-465 (1989).
14. 14. Piver, M. S., Lele, S. B., Marchetti, D. L., Baker, T. R., Tsukada, Y., and Emrich, L. J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma, J. Clin. Oncol. 6, 983-989 (1988).
15. 15. Del Campo, J. M., Felip, E., Rubio, D., Vidal, R., Bermejo, B., Colomer, R., and Zanon, V. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment, Gynecol. Oncol. 53, 27-32 (1994).
16. 16. Serov, S. F., Scully, R. E., and Sobin, L. J. Histological typing of ovarian tumors, in International histological classification of tumors, Geneva, World Health Organization, Geneva (1973).
17. 17. Day, T. G., Gallagher, H. S., and Rutledge, F. N. Epithelial carcinoma of the ovary: Prognostic importance of histologic grade. Natl. Cancer Inst. Monogr. 42, 15-18 (1975).
18. 18. Statview 4.5 Software Program, Abacus Concepts.
19. 19. Goodman, H. M., Harlow, B. L., Sheets, E. E., Muto, M. G., Brooks, S., Steller, M., Knapp, R. C., and Berkowitz, R. S. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma, Gynecol. Oncol. 46, 367-371 (1992).
20. 20. Curtin, J., Malik, R., Venkatraman, E., Barakat, R., and Hoskins, W. Surgical debulking of patients with stage IV ovarian cancer: Impact on survival, Gynecol. Oncol. 56, 129 (1995).
21. 21. Chen, S. S., and Bochner, R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma, Gynecol. Oncol. 20, 190-195 (1985).
22. 22. Potter, M. E., Partridge, E. E., Hatch, K. D., Soong, S-J., Austin, J. M., and Shingleton, H. M. Primary surgical therapy of ovarian cancer: How much and when, Gynecol. Oncol. 40, 195-200 (1991).
23. 23. Hoskins, W. J., Bundy, B. N., Thigpen, J. T., and Omura, G. A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study, Gynecol. Oncol. 47, 159-166 (1992).
24. 24. Lawton, F. G., Redman, C. W. E., Luesley, D. M., Chan, K. K., and Wharton, J. T. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer, Obstet. Gynecol. 73, 61-65 (1989).
25. 25. Jacob, J. H., Gershenson, D. M., Morris, M., Copeland, L. J., Burke, T. W., and Wharton, J. T. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer, Gynecol. Oncol. 42, 146-150 (1991).
26. 26. Schwartz, P. E., Chambers, J. T., and Makuch, R. Neoadjuvant chemotherapy for advanced ovarian cancer, Gynecol. Oncol. 53, 33-37 (1994).
27. 27. Lim, J. T. W., and Green, J. A. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma, Clin. Oncol. 5, 198-202 (1993).
28. 28. Nelson, B. E., Rosenfield, A. T., and Schwartz, P. E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma, J. Clin. Oncol. 11, 166-172 (1993).